Ann: Kazia's paxalisib awarded Orphan Drug Designation, page-16

I think Kazia currently haven’t applied for FTD for DIPG and this is implied in the below comment from the announcement today. (That is not to say they wont apply in the future though).

“...This award of ODD concludes a program of regulatory optimisation that Kazia has initiated for paxalisib over the past six months...”

Also, it might be worth noting that there likely will be some added benefit from the FTD process for glioblastoma for other indications as the marketing application would contain some similar components.